BPH Global (ASX:BP8) clocks A$3.4m sales and quietly buries the kefir story

A 156% revenue ramp and seven verticals reframe BP8 from beverage punt to vertically integrated seaweed supply chain

BPH Global (ASX:BP8) has dropped its June 2026 investor presentation and the framing is noticeably different from what we wrote about a few months ago. The seaweed kefir powder story we covered earlier this year is still in there, but it now sits as one near-term opportunity inside a much broader pitch.

The new frame is seven verticals, one feedstock, and an Indonesian supply chain doing real revenue. BPH is claiming A$3.4 million of gross sales in the first 12 months of its trading operation, with 156.5% revenue growth since month one and a Makassar warehouse hub scaling toward 1,000 metric tonnes per month.

That is a meaningful pivot in how investors are being asked to value this name. The market cap is still tiny at A$4.7 million with A$0.7 million of cash. The question is whether the trading revenue is enough to anchor a sum-of-the-parts story while the R&D verticals slowly mature.

The trading business is now the anchor, not the science

When we last wrote about BPH, the story turned on a S$15,260 lab contract with Singapore Polytechnic to develop a freeze-dried seaweed kefir powder. That was framed as a strategic pivot from finished beverages to ingredient supply.

Six months on, the presentation barely mentions kefir. The lead number is now the trading and supply chain business out of Indonesia, where BPH is sourcing raw seaweed biomass and selling it into export markets.

Trading businesses scale on volume and relationships, not on patents and lab work. The bull read is that BPH has quietly built a real cash-generating operation while the market was watching the R&D headlines. The skeptical read is that low-margin biomass trading is a tough place to defend a valuation re-rating.

Seven verticals is a lot for a A$4.7m company

The presentation lays out seven application verticals ranging from biostimulants in agriculture to pharmaceutical extracts. Each comes attached to a credible research partner, including Temasek Polytechnic, BRIN Indonesia and UNIDO.

We think this is where investors need to read carefully. The partner list is genuinely strong for a company this size. But seven verticals is a focus problem dressed up as an opportunity slide.

Our concern is that A$0.7 million of cash cannot meaningfully fund seven parallel development tracks. The realistic read is that two or three of these verticals matter, and investors should be watching which ones management actually puts capital and time behind over the next two quarters.

The Indonesian innovation centre is where the real capital ask sits

The phased investment plan for the South Sulawesi innovation centre tells you where the next funding round is going. Phase 1 targets IDR 8.4 billion (roughly A$0.8 million). Phase 3 targets a further IDR 17.6 billion for commercialisation.

Combined, that is roughly A$2.5 million of build-out spending against a current cash balance of A$0.7 million. The maths only works with either a meaningful capital raise, a sponsored research grant, or a sharp acceleration in trading cash flow.

Worth noting that Sea Forest, referenced as a market validation comp, sits at roughly A$140 million market cap on a single cattle feed product. BPH is implicitly arguing the multi-vertical model deserves a re-rating toward that kind of valuation. That is a long bridge to cross from here.

The Investors Takeaway for BPH Global

The presentation does a good job of repositioning BPH from a niche beverage pivot story into a vertically integrated seaweed platform. Investors who held through the kefir narrative now have a broader thesis to evaluate.

What we want to see next is the trading business margin profile. A$3.4 million of gross sales is meaningful for a A$4.7 million company, but only if the gross margin justifies the working capital tied up in scaling a Makassar warehouse to 1,000 tonnes a month.

Readers who want the earlier context on the kefir pivot can find our prior coverage at stocksdownunder. The next twelve months will tell us whether BPH has built a platform or a presentation.